Stock Ratings / Health Care / DWTX / news

GRCE (35) ATHE (58) ANVS (40) ALDX (50) ⌘ Pro Terminal →

Why DWTX Stock slipped -0.81% Today — RQD Quant Desk Flash

$1.23 -0.81% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Dogwood Therapeutics Inc. (DWTX) carries a Roarable Rating of D- (Sell) with 41/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $41.8M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-7.3% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for DWTX)Realized 20D OHLCV Swing Band: ±12.5%

AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →

Why DWTX Stock slipped -0.81% Today — RQD Quant Desk Flash

Dogwood Therapeutics Inc. (DWTX) slipped -0.81% to $1.23, trading at 3% of its 52-week range ($1.07 – $7.04). Stretched risk/reward at current multiples (-32% return on capital) under elevated 10-year interest-rate pressure.

▸Technical Tape: Trading at 3% of its 52-week range ($1.07 – $7.04) with RSI-14 at 44.1 (NEUTRAL RANGE).
▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $1.23 (no active unusual options sweep snapshot on file).
▸Fundamental Anchor: Roarable D- (Sell) backed by 52% gross margin and $0 annual free cash flow.

Live DWTX Headlines & Catalysts

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring DWTX)

✓Walkthrough of DWTX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

DWTX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -13.99%📐 HORIZONTAL RANGE

2026-10-30O $1.30H $1.36L $1.23C $1.23VOL 57.8K

RES: $3.33SUP: $1.06SMA50: $1.68SMA200: $1.98

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

DWTX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 DWTX Butterfly Map → + Track DWTX →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on DWTX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for DWTX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for DWTX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (DWTX)

Health Care Rank #619 of 1016 ⚔️ GRCE vs DWTX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (DWTX vs. GRCE, ATHE, ANVS, ALDX)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Dogwood Therapeutics Inc. (DWTX) ranks #619 by composite RQD confidence (41/100, grade D-) and #769 by equity capitalization ($41.8M). Within this direct 5-issuer industry benchmark cohort, DWTX leads on earnings valuation at N/A trailing P/E, while GRCE leads on capital efficiency and profitability with -18.9% ROIC and — gross margin. ATHE currently holds the highest overall quantitative score in the immediate peer group at 58/100 (D+) compared with DWTX at 41/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
DWTX ACTIVE Dogwood Therapeutics Inc.	D-	41/100	—	—	-32.3%	-0.81%	$41.8M	Benchmark Subject
GRCE Grace Therapeutics Inc.	D-	35/100	—	—	-18.9%	-3.48%	$40.8M	/grce-vs-dwtx →
ATHE Alterity Therapeutics Limited	D+	58/100	—	—	—	+2.93%	$40.7M	/athe-vs-dwtx →
ANVS Annovis Bio Inc.	D-	40/100	—	—	-35.0%	0.00%	$43.5M	/anvs-vs-dwtx →
ALDX Aldeyra Therapeutics Inc.	D	50/100	—	—	-35.0%	-3.58%	$39.8M	/aldx-vs-dwtx →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001818844

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Dogwood Therapeutics Inc. (DWTX) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$34.3M, operating cash flow of -$15.6M, and free cash flow of -$15.6M (-77.7% YoY). On the balance sheet, DWTX closed FY2025 with $90.2M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$34.3M	-$15.6M	-$15.6M	$90.2M	—
FY2024 (FY)	2024-12-31	$0	-$12.3M	-$8.8M	-$8.8M	$94.3M	—
FY2023 (FY)	2023-12-31	$0	-$5.3M	-$4.9M	-$4.9M	—	—

3. DWTX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is DWTX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Dogwood Therapeutics Inc. (NASDAQ: DWTX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 41/100 at a spot price of $1.23 (-0.81% 1D, market cap $41.8M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, DWTX ranks #619 in composite RQD confidence.

How does DWTX compare to GRCE and ATHE in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), DWTX carries a Roarable D- (41/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -32.3%. By comparison, GRCE (Grace Therapeutics Inc.) holds a D- grade (35/100 RQD, P/E N/A, ROIC -18.9%, cap $40.8M) and ATHE (Alterity Therapeutics Limited) posts a D+ grade (58/100 RQD, P/E N/A, ROIC —, cap $40.7M). Among the 5-stock peer group, DWTX leads on earnings multiple (N/A) while GRCE leads on capital efficiency (-18.9% ROIC).

What are the biggest fundamental strengths and SEC risk factors for DWTX?

Per DWTX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001818844), Dogwood Therapeutics Inc. generated $0 in revenue, -$34.3M in net income, and -$15.6M in free cash flow against $90.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is DWTX trading relative to its 50-day, 200-day, and 52-week technical levels?

DWTX last traded at $1.23 (-0.81% on volume of 95,932 shares), positioning the stock -26.79% below its 50-day simple moving average ($1.68) and -37.88% below its 200-day simple moving average ($1.98). Across its 52-week range of $1.07 to $7.04, DWTX sits at the 2.7% percentile with a 14-day RSI of 44.1 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.08 to $1.38).

DWTX Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Why is DWTX stock moving today?

Why DWTX Stock slipped -0.81% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-32% return on capital) under elevated 10-year interest-rate pressure.

Direct Sub-Reports: DWTX RQD Cockpit DWTX 12M Forecast DWTX Earnings & Move DWTX Dividends & DRIP DWTX Insiders & 13F DWTX Whale Options DWTX Profit Sankey DWTX News & Why